MOROCCO — Independent private equity firm SPE Capital has unveiled the impending sale of Amanys Pharma to Laprophan, a pioneering pharmaceutical company in Morocco.

The transaction, subject to regulatory approvals, marks the second exit for SPE AIF, the US$260 million African-focused fund managed by SPE Capital, which concluded its final close in December 2020.

The strategic collaboration between Laprophan and Amanys Pharma, supported by a consortium of investors led by Mediterrania Capital Partners (MCP), is poised to reshape the pharmaceutical landscape in Morocco and extend its influence across Africa.

The partnership aims to establish a diversified pharmaceutical group, capitalizing on the specialized and complementary divisions of both Laprophan and Amanys.

Since SPE Capital and Proparco’s acquisition of Amanys in 2020, they have actively supported the management team in achieving sustained growth, expanding industrial capabilities, and enhancing governance standards.

Amanys Pharma, a pharmaceutical group established in 2011, specializes in the manufacturing of antibiotics and hospital specialty drugs.

The company serves customers in Morocco and sub-Saharan Africa, offering a range of products, including antibiotics and drugs for hemophilia, oncology, anesthesia, and intensive care units.

Laprophan, a leading pharmaceutical laboratory in Africa founded in 1949, has a rich tradition of research and development.

The company has significantly contributed to Morocco’s public health sector by inventing and patenting innovations globally. Laprophan markets over 400 products across various therapeutic areas.

Farid Bennis, Laprophan’s CEO, expressed confidence in the synergy between the two pharmaceutical players, stating, “I am convinced that this coming together of two pharmaceutical players with real synergies will serve the interests of patients in Morocco and more broadly in Africa.”

Mly Younous Elalamy, General Manager of Amanys, highlighted their enthusiasm for the partnership, ensuring the continuation of the group’s development while leveraging industrial and commercial complementarities.

Nabil Triki, Managing Partner and CEO of SPE Capital, expressed pride in the company’s achievements and its support for Amanys’ ambitious development plan.

Tibor Asboth, Deputy Head of the Private Equity team for Africa and the Middle East at Proparco, emphasized Proparco’s commitment to local production and access to quality essential medicines in Morocco and across Africa.

The deal was facilitated by legal advisors DLA Piper and financial advisors KPMG for SPE Capital. Laprophan received legal counsel from ASAFO & Co. and financial advisory services from Deloitte Maroc.

The legal advisory team from Asafo & Co., led by partners Patrick Larrivé and Mouna Boubia, played a crucial role in the transaction, with Deloitte Maroc contributing as the financial advisor for Laprophan.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.